Limits...
Antiviral Activity of Gold/Copper Sulfide Core/Shell Nanoparticles against Human Norovirus Virus-Like Particles.

Broglie JJ, Alston B, Yang C, Ma L, Adcock AF, Chen W, Yang L - PLoS ONE (2015)

Bottom Line: Increasing nanoparticle concentration and/or VLP-NP contact time significantly increased the virucidal efficacy of Au/CuS NPs.Changes to the VLP particle morphology, size, and capsid protein were characterized using dynamic light scattering, transmission electron microscopy, and Western blot analysis.The strategy reported here provides the first reported proof-of-concept Au/CuS NPs-based virucide for rapidly inactivating human norovirus.

View Article: PubMed Central - PubMed

Affiliation: Biomanufacturing Research Institute and Technology Enterprise (BRITE), Department of Pharmaceutical Sciences, North Carolina Central University, Durham, North Carolina, United States of America.

ABSTRACT
Human norovirus is a leading cause of acute gastroenteritis worldwide in a plethora of residential and commercial settings, including restaurants, schools, and hospitals. Methods for easily detecting the virus and for treating and preventing infection are critical to stopping norovirus outbreaks, and inactivation via nanoparticles (NPs) is a more universal and attractive alternative to other physical and chemical approaches. Using norovirus GI.1 (Norwalk) virus-like particles (VLPs) as a model viral system, this study characterized the antiviral activity of Au/CuS core/shell nanoparticles (NPs) against GI.1 VLPs for the rapid inactivation of HuNoV. Inactivation of VLPs (GI.1) by Au/CuS NPs evaluated using an absorbance-based ELISA indicated that treatment with 0.083 μM NPs for 10 min inactivated ~50% VLPs in a 0.37 μg/ml VLP solution and 0.83 μM NPs for 10 min completely inactivated the VLPs. Increasing nanoparticle concentration and/or VLP-NP contact time significantly increased the virucidal efficacy of Au/CuS NPs. Changes to the VLP particle morphology, size, and capsid protein were characterized using dynamic light scattering, transmission electron microscopy, and Western blot analysis. The strategy reported here provides the first reported proof-of-concept Au/CuS NPs-based virucide for rapidly inactivating human norovirus.

No MeSH data available.


Related in: MedlinePlus

Particle size and appearance after treatment.(A) Mean size of small particles (<10 nm) in treated and untreated VLP solutions. VLP solutions at 5.6 μg/mL were dosed with 2.08 μM Au/CuS NPs, and all solutions were rotated end-over-end and centrifuged for 10 and 5 min, respectively. Particle size was measured using dynamic light scattering. (B) TEM images of untreated VLPs, and VLPs treated with 0.083 μM and 0.83 μM for 30 min. Arrows indicate examples of untreated VLPs which are round shaped circles in light color and aggregated together; Treatment with 0.083 μM NPs caused VLPs lost integrity in the aggregate; Treatement with 0.83 μM NPs caused VLPs to break down into fragments and no intact VLP can be seen.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4608711&req=5

pone.0141050.g004: Particle size and appearance after treatment.(A) Mean size of small particles (<10 nm) in treated and untreated VLP solutions. VLP solutions at 5.6 μg/mL were dosed with 2.08 μM Au/CuS NPs, and all solutions were rotated end-over-end and centrifuged for 10 and 5 min, respectively. Particle size was measured using dynamic light scattering. (B) TEM images of untreated VLPs, and VLPs treated with 0.083 μM and 0.83 μM for 30 min. Arrows indicate examples of untreated VLPs which are round shaped circles in light color and aggregated together; Treatment with 0.083 μM NPs caused VLPs lost integrity in the aggregate; Treatement with 0.83 μM NPs caused VLPs to break down into fragments and no intact VLP can be seen.

Mentions: We further investigated the particle size profiles in VLP suspensions before and post-NPs treatment using dynamic light scattering (DLS). Fig 4 shows the mean particle diameter profiles of VLP suspension, Au/CuS NPs suspension, and the VLP suspension after NP treatment. As expected, for the VLP suspensions, the peak between 10 to 100 nm represented the VLP particles in the suspension, as it is known that the diameter of an assembled norovirus VLP is ~38 nm [53], but smaller and larger particles with 20 to 90 nm diameter were also observed [55]. For the Au/CuS NP suspensions, the peak between 1 and 10 nm indicated the profile of the NPs diameters, which was very close to the previously reported size of 2–5 nm (as determined by SEM/TEM). For VLPs + Au/CuS NPs suspensions, it is obvious that the VLP peak disappeared after 10 min of mixing, suggesting that the intact VLPs may have broken into smaller fragments. Tests on VLP suspensions treated with NPs at other concentrations (0.83 μM and 1.245 μM) showed similar results where the peak between 10 and 100 nm before treatment shifted to <10 nm after NPs treatments (S1 Fig).


Antiviral Activity of Gold/Copper Sulfide Core/Shell Nanoparticles against Human Norovirus Virus-Like Particles.

Broglie JJ, Alston B, Yang C, Ma L, Adcock AF, Chen W, Yang L - PLoS ONE (2015)

Particle size and appearance after treatment.(A) Mean size of small particles (<10 nm) in treated and untreated VLP solutions. VLP solutions at 5.6 μg/mL were dosed with 2.08 μM Au/CuS NPs, and all solutions were rotated end-over-end and centrifuged for 10 and 5 min, respectively. Particle size was measured using dynamic light scattering. (B) TEM images of untreated VLPs, and VLPs treated with 0.083 μM and 0.83 μM for 30 min. Arrows indicate examples of untreated VLPs which are round shaped circles in light color and aggregated together; Treatment with 0.083 μM NPs caused VLPs lost integrity in the aggregate; Treatement with 0.83 μM NPs caused VLPs to break down into fragments and no intact VLP can be seen.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4608711&req=5

pone.0141050.g004: Particle size and appearance after treatment.(A) Mean size of small particles (<10 nm) in treated and untreated VLP solutions. VLP solutions at 5.6 μg/mL were dosed with 2.08 μM Au/CuS NPs, and all solutions were rotated end-over-end and centrifuged for 10 and 5 min, respectively. Particle size was measured using dynamic light scattering. (B) TEM images of untreated VLPs, and VLPs treated with 0.083 μM and 0.83 μM for 30 min. Arrows indicate examples of untreated VLPs which are round shaped circles in light color and aggregated together; Treatment with 0.083 μM NPs caused VLPs lost integrity in the aggregate; Treatement with 0.83 μM NPs caused VLPs to break down into fragments and no intact VLP can be seen.
Mentions: We further investigated the particle size profiles in VLP suspensions before and post-NPs treatment using dynamic light scattering (DLS). Fig 4 shows the mean particle diameter profiles of VLP suspension, Au/CuS NPs suspension, and the VLP suspension after NP treatment. As expected, for the VLP suspensions, the peak between 10 to 100 nm represented the VLP particles in the suspension, as it is known that the diameter of an assembled norovirus VLP is ~38 nm [53], but smaller and larger particles with 20 to 90 nm diameter were also observed [55]. For the Au/CuS NP suspensions, the peak between 1 and 10 nm indicated the profile of the NPs diameters, which was very close to the previously reported size of 2–5 nm (as determined by SEM/TEM). For VLPs + Au/CuS NPs suspensions, it is obvious that the VLP peak disappeared after 10 min of mixing, suggesting that the intact VLPs may have broken into smaller fragments. Tests on VLP suspensions treated with NPs at other concentrations (0.83 μM and 1.245 μM) showed similar results where the peak between 10 and 100 nm before treatment shifted to <10 nm after NPs treatments (S1 Fig).

Bottom Line: Increasing nanoparticle concentration and/or VLP-NP contact time significantly increased the virucidal efficacy of Au/CuS NPs.Changes to the VLP particle morphology, size, and capsid protein were characterized using dynamic light scattering, transmission electron microscopy, and Western blot analysis.The strategy reported here provides the first reported proof-of-concept Au/CuS NPs-based virucide for rapidly inactivating human norovirus.

View Article: PubMed Central - PubMed

Affiliation: Biomanufacturing Research Institute and Technology Enterprise (BRITE), Department of Pharmaceutical Sciences, North Carolina Central University, Durham, North Carolina, United States of America.

ABSTRACT
Human norovirus is a leading cause of acute gastroenteritis worldwide in a plethora of residential and commercial settings, including restaurants, schools, and hospitals. Methods for easily detecting the virus and for treating and preventing infection are critical to stopping norovirus outbreaks, and inactivation via nanoparticles (NPs) is a more universal and attractive alternative to other physical and chemical approaches. Using norovirus GI.1 (Norwalk) virus-like particles (VLPs) as a model viral system, this study characterized the antiviral activity of Au/CuS core/shell nanoparticles (NPs) against GI.1 VLPs for the rapid inactivation of HuNoV. Inactivation of VLPs (GI.1) by Au/CuS NPs evaluated using an absorbance-based ELISA indicated that treatment with 0.083 μM NPs for 10 min inactivated ~50% VLPs in a 0.37 μg/ml VLP solution and 0.83 μM NPs for 10 min completely inactivated the VLPs. Increasing nanoparticle concentration and/or VLP-NP contact time significantly increased the virucidal efficacy of Au/CuS NPs. Changes to the VLP particle morphology, size, and capsid protein were characterized using dynamic light scattering, transmission electron microscopy, and Western blot analysis. The strategy reported here provides the first reported proof-of-concept Au/CuS NPs-based virucide for rapidly inactivating human norovirus.

No MeSH data available.


Related in: MedlinePlus